How effective is Mobocertinib/Mobocertinib in non-small cell lung cancer?

Mobocertinib/Mobocertinib(Mobocertinib) is the first drug to treat EGFRexon20Insert(EGFRex20ins)positive non-small cell lung cancer(non-small cell lung cancer)EGFRtyrosine kinase inhibitor. Mobotinibis indicated for the treatment of patients with locally advanced or metastatic EGFRex20inspositive non-small cell lung cancer who have progressed during or after platinum-based chemotherapy.

2021Year9 month, FDA accelerated approval of mobotinib based on a clinical study named Study 101. The study included 114 patients with non-small cell lung cancer that had spread to other parts of the body and could not be removed with surgery. These patients have EGFR exon 20 insertion mutations in their lung cancers, which are identified by a special test. Patients are receiving or have previously received platinum-containing chemotherapy and their diseasehasprogressed. In the study, participants received 160 milligrams of oral mobotinib once daily until their lung cancer worsened or they developed intolerable side effects. The effectiveness of mobotinib was determined by observing overall response rate (ORR) and duration of response (DoR).

Overall, about28%of people(32/114) had a partial response tomobotinibtreatment, and the response lasted about17.5 months. Nearly 59%of patients who responded (19/32) had responses that lasted at least 6 months. The median overall survival was 24 months(2year). The median is when half the population lives more than 24 months and the other half lives less than 24 months. The price of generic drugs is favorable, ranging from 3 to more than 4 thousand per box. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0